Zydus Pharmaceuticals (USA) Inc, located in Pennington, New Jersey, is looking forward to its future in the US pharmaceutical market. Since its first commercial launch in August 2005, it has grown steadily over the past 7 years and now offers more than 260 SKUs to the US market. For the seventh straight year, IMS Health has recognized Zydus as one of the fastest growing pharmaceutical companies by total prescriptions dispensed. IMS Health also listed Zydus in the top 10 (ranked number 10) US generic companies based on total prescriptions dispensed.
This is an exciting time for Zydus as the company continues to expand its portfolio to offer new dosage forms and enter different franchises within the US pharmaceutical market. With the purchase of Nesher Pharmaceuticals in St. Louis, Missouri, Zydus has a footprint in the US that has allowed the company to enter the controlled substances sector. Zydus has also launched its first injectable product (Ranitidine HCl injection) this past year. In the near future, Zydus hopes to introduce nasal sprays for the first time in the US. Zydus is also aggressively pursuing other franchises, such as dermatologic and oncology products, as well as metered dose inhalers. The company has worked extremely hard to put together a rich product pipeline for the future.
Zydus Pharmaceuticals’ parent company, Zydus Cadila, is India’s fifth-largest pharmaceutical company and has experienced tremendous growth over the past several years. It is a global pharmaceutical company with business operations in more than 50 countries, including the United States, European countries, Japan, Spain, Brazil, and Mexico. With more than 14,000 employees across 26 countries, India’s largest finished dosage plant under 1 roof, 2 FDA-approved API sites, and the ability to manufacture a wide variety of dosage forms, Zydus Cadila is more than ready to support the rapidly growing US pharmaceutical market. With the FDA approval of its Baddi plant and its newest manufacturing plant completed, Zydus will soon have a pill and capsule capacity exceeding 20 billion annually.
With the strength and worldwide reputation of Zydus Cadila supporting the US division, Zydus Pharmaceuticals is looking forward to continuing its growth in the US marketplace. As the company focuses its efforts on more challenging and rewarding opportunities, including several first-to-file and 505B2 opportunities, it looks forward to great success as the company expands. To date, Zydus has filed 112 drug master files (DMFs), received 74 Abbreviated New Drug Application (ANDA) final and tentative approvals, and has 84 ANDAs pending approval with the FDA. Look for some exciting announcements from Zydus over the next 12 months, as it is truly “poised for the future.”
You can visit Zydus Pharmaceuticals (USA) Inc. at NACDS Pharmacy and Technology at booth 2808 or learn more about the company through its website at www.zydususa.com